Company news

Viridian Therapeutics, Inc. news in 2024

Viridian Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

December 15, 2024

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

December 12, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

November 11, 2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

September 10, 2024

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

September 9, 2024

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

September 9, 2024

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

September 8, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

August 7, 2024

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

July 24, 2024

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

June 10, 2024

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 30, 2024

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 9, 2024

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 7, 2024

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

April 28, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 4, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

February 26, 2024

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

February 15, 2024

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

January 16, 2024

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

January 7, 2024

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Calls in 2024

Decks in 2024